Overview
Recruiting start date
Duration
Population
2 Years to 11 Years (Child ) with NonSegmental Vitiligo
Study Drug
Ruxolitinib Cream
Inclusion Criteria
Exclusion Criteria
What You Can Expect
The study will include visits to our study center where the patient will initially receive a thorough physical examination, including an EKG and blood work at no cost to the patient to assess the participant’s baseline health. Moreover, the patient will receive a screening examination from a dermatology specialist to confirm the diagnosis of the study disease. After informed consent and if the participant elects to continue in the study, the patient will either be given the active medication (i.e. Ruxolitinib ) or a placebo. There will be regular follow-up visits to assess the effectiveness and safety of the therapies.